Deepika Singh’s Post

Proud of the Flatiron and NCCN collaboration enabling a learning healthcare system and furthering our mission to learn from and improve every person’s experience with cancer!

💡 Insightful and short talk for anyone focused on Breast Cancer research, especially relating to ADCs. The speaker and panelists discussed: - How physicians are grappling with optimal ADC sequencing given shorter PFS for the second ADC vs the first ADC and limited available data to inform decision making - Factors that influence sequencing (direct vs sandwiching) - biomarker status, tolerability - AEs and their grade + management, burden and pace of disease, and dosing schedule Thanks Nathan Hubbard for sharing. https://lnkd.in/eX2Utawx

🚀 Exciting News in Oncology Research! 🌟 The depth of Flatiron Health clinical data, curated with over a decade of Oncology RWE expertise, coupled with Caris Life Sciences Whole Exome and Whole Transcriptome sequencing coverage is an unmatched offering. Our life sciences partners are buzzing with excitement, and I can't help but share a direct quote that perfectly captures the spirit of innovation: "The depth of real world clinical data matched with WES & WTS will unlock research questions that previously weren't on the table." 🚀🤔💡 Thrilled to be at the forefront of groundbreaking research, we're turning possibilities into realities. #rwe #oncology #clinicalresearch

Let's talk about bridging the gap from research to care at SABCS! 🚀 As metastatic breast cancer treatments shift to the early stages, what will be the future of treatment sequencing post-progression?  🔄 With a plethora of targeted therapies emerging, how do we help understand and define optimal sequencing in the 2L setting and beyond? 🧬📊 Let’s talk about the intricate interplay between testing, treatment strategies, and their intersection with social determinants of health. 💊 How do dosing patterns and adverse events shape the landscape of treatment sequencing? If you're passionate about deciphering these complexities, let's connect! 🤝 Join Catherine K., Shea Gillet, PhD, and me at SABCS  #SABCS23 #SABCS #OncologyInnovation #ScientificExchange

Collaborations like these transform evidence generation. At Flatiron Health, we're honored to partner with Janssen Inc., especially innovative leaders such as Khaled Sarsour, Ashita Batavia, MD, MS, Jennifer Hayden, to develop methods to correct for misclassification bias and surveillance bias in Multiple Myeloma. Method development in this space will enable regulatory decision making and drug access for patients! #rwd #multiplemyeloma

🚀 Thrilled to Share My Next Chapter at Flatiron Health! I'm delighted to announce my new role, VP Life Sciences, leading Flatiron Health's partnerships with Life Sciences companies ⚕ Working with our biopharma partners, I’ve seen first hand how real-world evidence solutions and services can power the possibilities of oncology research, development, and commercialization. In this expanded role, I’ll have the opportunity to strengthen our longstanding partnerships and forge new ones, as we scale RWE solutions and services, leveraging data from 🇺🇸 🇩🇪 🇬🇧 🇯🇵 . I couldn't be more excited for this journey. I'm deeply grateful for this opportunity and look forward to the challenges and triumphs that lie ahead. Thanks to the incredible team at Flatiron Health for their unwavering support. Nathan Hubbard looking forward to partnering closely with you in your new role! 💪 #flatironhealth #rwe #lifesciences #biopharma #evidence

If you are at #ESMO23 and passionate about answering research questions on cancer care in UK, Germany, Japan and US, learning from 30+ HTA submissions, or engaging in research collaborations on evidence gaps in evaluating new oncology medicines, meet Flatiron experts like Javier Jimenez, Michael Bierl, Blythe Adamson, PhD, MPH, and Nathan Hubbard.

In 2023, we've witnessed incredible progress in breast cancer research, (potentially) bringing new treatment options to people with breast cancer and their caregivers! These developments prompt more research on their real-world impact, and that's what gets me excited on a Tuesday morning! 🌟 At Flatiron, we are privileged to have the data and expertise to help answer questions about how people get treated in the real world: 💡 The SONIA trial challenged the need for first-line use of a CDK4/6 Inhibitor in HR+, HER2- Advanced Breast Cancer. The results open up research on treatment sequencing in the real world, considering safety and cost. 💊 The NATALEE trial's interim analysis revealed an improvement in Invasive Disease-Free Survival when adding a CDK4/6 Inhibitor to endocrine therapy as adjuvant treatment for HR+,HER2- Early Breast Cancer patients. This finding holds great promise! Will physicians seek evidence to determine which patients can benefit from CDK4/6 inhibitors in the adjuvant setting? How will decision-making differ for patients with different risk levels or age groups? ⏰ The FDA granting priority review for an AKT inhibitor is a positive step forward for patients with HR+, HER2- advanced breast cancer who progressed on endocrine therapy (with and without CDK 4/6 inhibitors). What are the current treatment options and outcomes for these patients in the real world? 💬 If you are passionate about exploring these and other questions, I’d love to hear from you! #rwe #breastcancer #flatironhealth

Excited to be able to leverage the expertise Flatiron gained over 11+ years of exclusive focus on Oncology RWD to support use cases across the drug lifecycle. It is very rewarding to help transform RWD to insights that help refine clinical trial strategy and evidence that supports reimbursement decisions.